TYMS

Thymidylate synthase · P04818 · TYMS on Sugi Atlas →

43,173 patent compounds predicted against TYMS, 24,843 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Nolatrexed (SCHEMBL316632)	0.97	20/20
Nolatrexed (SCHEMBL18489)	0.66	20/20
SCHEMBL328456	0.55	12/20
Raltitrexed (SCHEMBL7439)	0.78	9/20
SCHEMBL322393	0.62	9/20
SCHEMBL166747	0.49	9/20
Raltitrexed (SCHEMBL7438)	1.00	8/20
Raltitrexed (SCHEMBL13959)	1.00	8/20
1,8-Naphthalic Anhydride (SCHEMBL30415)	1.00	8/20
SCHEMBL93906	0.41	8/20
SCHEMBL94872	0.77	7/20
SCHEMBL208257	0.62	7/20
SCHEMBL464402	0.71	6/20
SCHEMBL464379	0.70	6/20
Thymidine Monophosphate (SCHEMBL349694)	0.64	6/20
Deoxyuridine Monophosphate (SCHEMBL8200)	0.63	6/20
SCHEMBL13971	0.63	6/20
Pemetrexed (SCHEMBL208289)	0.62	6/20
SCHEMBL148025	0.62	6/20
SCHEMBL14329	0.59	6/20

Clinical trials — most relevant to TYMS by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis	PHASE3	COMPLETED
A Phase II Study of TX Regimen as First-line Treatment for Asian Elderly Patients With Advanced Adenocarcinoma of Lung	PHASE2	COMPLETED
Prospective Phase II Randomized Trial of Postoperative Adjuvant Chemotherapy in Patients With High Risk Colon Cancer	PHASE2	UNKNOWN
A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers	PHASE2	COMPLETED
Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer	PHASE2	UNKNOWN
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer	PHASE2	COMPLETED
Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery	PHASE2	COMPLETED
Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study	PHASE2	UNKNOWN
Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers	PHASE2	WITHDRAWN
Response Prediction in Metastasized Colorectal Cancer Using Intratumoral Thymidylate Synthase	PHASE2	COMPLETED
TS Gene Polymorphism Predicts Effect in Patients With Advanced Lung Cancer	PHASE2	COMPLETED
Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer	PHASE2	COMPLETED
Combination Chemotherapy Followed by Surgery and Intraperitoneal Chemotherapy in Treating Patients With Locally Advanced Stomach Cancer	PHASE2	COMPLETED
Study of S-1 as Second Line Treatment on Advanced Pancreatic Cancers	PHASE2	UNKNOWN
S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer	PHASE2	COMPLETED
Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene	PHASE2	COMPLETED
Capecitabine and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer	PHASE1/PHASE2	COMPLETED
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors	PHASE1	COMPLETED
Study of Capecitabine In Patients With Solid Tumors	PHASE1	COMPLETED
Irinotecan and Capecitabine in Treating Patients With Solid Tumors	PHASE1	COMPLETED
Phase I Study of 5-Fluorouracil in Children and Young Adults With Recurrent Ependymoma	PHASE1	COMPLETED
MNGIE Allogeneic Hematopoietic Stem Cell Transplant Safety Study	PHASE1	WITHDRAWN
Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors	PHASE1	COMPLETED
TS Overexpression in SCLC: Mechanism and Therapeutic Targeting	nan	COMPLETED
C677T and A1298C MTHFR Polymorphisms and Fluoropyrimidine Effectiveness in Metastatic Colon Cancer	nan	UNKNOWN
Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to 5-Fluorouracil Based Chemotherapy in Stage III Colon Cancer	nan	UNKNOWN
The Natural History Study of Mitochondrial NeuroGastroIntestinal Encephalopathy (MNGIE)	nan	RECRUITING
Study of S1 Efficacy and Toxicity as Second-line Treatment on Inoperable or Advanced Gastric Cancers	nan	UNKNOWN
Evaluation of Thymidine Kinase Activity in the Serum of Patients With Solid Tumors	nan	UNKNOWN
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a TYMS binder may also engage these)

Protein	Name	Similarity
P45352	—	1.000	P45352 →
P07607	—	1.000	P07607 →
E0U0H8	—	1.000	E0U0H8 →
P09249	—	1.000	P09249 →
A7Z5T3	—	1.000	A7Z5T3 →
A1U3D8	—	1.000	A1U3D8 →
P54081	—	1.000	P54081 →
Q4JQW2	—	1.000	Q4JQW2 →
Q5FKL6	—	1.000	Q5FKL6 →
Q738X7	—	1.000	Q738X7 →
B7GI39	—	1.000	B7GI39 →
C3MEE8	—	1.000	C3MEE8 →
Q2K6G8	—	1.000	Q2K6G8 →
Q8G3T9	—	1.000	Q8G3T9 →
Q5L9L6	—	0.999	Q5L9L6 →
Q8FR47	—	0.999	Q8FR47 →
Q64PV5	—	0.999	Q64PV5 →
A6L1Q8	—	0.999	A6L1Q8 →
C1KWH4	—	0.999	C1KWH4 →
Q1ME82	—	0.999	Q1ME82 →
Q71YE1	—	0.999	Q71YE1 →
Q32C94	—	0.999	Q32C94 →
Q168V8	—	0.999	Q168V8 →
Q92AD4	—	0.999	Q92AD4 →
A6LIC2	—	0.999	A6LIC2 →
Q04B29	—	0.999	Q04B29 →
B1IU17	—	0.999	B1IU17 →
Q98KH9	—	0.998	Q98KH9 →
B7LNI2	—	0.998	B7LNI2 →
A1TM53	—	0.998	A1TM53 →